Vilokin Yoga Group

Survival rates for osteosarcoma in the United States vary significantly based on the stage at diagnosis. For localized disease, the 5-year relative survival rate in 2026 is approximately 70% to 75%.

However, for patients where the cancer has already spread to the lungs or other bones at diagnosis, the survival rate drops to roughly 30%. US clinicians use several prognostic markers to tailor therapy, including the patient's age, the location of the tumor (pelvic tumors generally have a worse prognosis than limb tumors), and the presence of biomarkers like P-glycoprotein, which is associated with chemotherapy resistance.